Refractory hypoglycemia is sensitive to octreotide therapy: is it triggered by sorafenib or hepatocellular carcinoma?

Autor: Çakmak M; Department of Medical Oncology., Bal Ö; Department of Medical Oncology., Kiraci M; Department of Medical Oncology., Topaloğlu O; Department of Endocrinology and Metabolic Diseases, University of Health Science, Bilkent City Hospital, Ankara, Turkey., Köş FT; Department of Medical Oncology., Algin E; Department of Medical Oncology.

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2024 Dec 03. Date of Electronic Publication: 2024 Dec 03.

An aggressive Cushing's syndrome originating from a rare thymic neuroendocrine tumor, controlled successfully with fluconazole and octreotide therapy before surgery.

Autor: Kargun S; Department of Endocrinology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Aydemir M; Department of Endocrinology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Yilmaz N; Department of Endocrinology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Gürer İE; Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Sari R; Department of Endocrinology, Akdeniz University Faculty of Medicine, Antalya, Turkey., Altunbas H; Department of Endocrinology, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Publikováno v: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Aug 16. Date of Electronic Publication: 2024 Aug 16.

Efficacy of long-term octreotide therapy of acromegaly as the first-line medical treatment

Autor: L. K. Dzeranova, M. I. Yevloyeva, M. A. Perepelova, E. A. Pigarova, A. S. Shutova, A. V. Dorovskikh, V. N. Azizyan, E. G. Przhiyalkovskaya

Publikováno v: Ожирение и метаболизм, Vol 20, Iss 1, Pp 66-72 (2023)

Acromegaly is a severe neuroendocrine disease characterized by hypersecretion of growth hormone (GH) caused in 95% of cases by pituitary adenoma, which leads to the development of pathology of various organs and systems. The severity of the condition

Externí odkaz: https://doaj.org/article/ad0f04113fc14f3b918d8d28dea9a6b5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-Reported Symptoms in Patients Responsive To Prior Octreotide Therapy And Patients Naïve To Somatostatin Analogue Therapy in The Elect Phase 3 Study

Autor: Fisher, George A., Jr. ^*, Wolin, Edward M., Liyanage, Nilani, Lowenthal, Susan Pitman, Mirakhur, Beloo, Pommier, Rodney F., Shaheen, Montaser ^*, Vinik, Aaron I.

Publikováno v: In Endocrine Practice March 2018 24(3):243-255